---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122279"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:44:41.483066+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Janux reports Q3 net loss $28.1M; cash $658M; JANX007 update expected by year-end

## Summary
- Cash and short-term investments $658.0M at Sept 30, 2024 vs $344.0M at Dec 31, 2023.
- Net loss $28.1M for Q3 2024 vs $11.6M in Q3 2023; R&D expenses $18.6M vs $11.9M.
- G&A expenses $17.7M for Q3 2024 including $9.5M stock-based compensation from equity modifications.
- Enrollment continues for JANX007 (PSMA-TRACTr) in mCRPC and JANX008 (EGFR-TRACTr) in solid tumors.
- Update on JANX007 data and expansion cohort doses anticipated in 2024; JANX008 update in 2025.

## SEC filing metadata
- accession: 0000950170-24-122279
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017024122279/0000950170-24-122279-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017024122279/janx-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122279
- JSON: https://secwatch.observer/filing/0000950170-24-122279.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122279.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.